Hypercalcemia has been reported to occur in up to 30% of patients who have a malignancy. Hypercalcemia is most common in those who have later-stage malignancies and predicts a poor prognosis for those ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

Accelerating treatment decisions with liquid biopsy NGS in non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...

The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.

Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for cancer patients. Enoby targets bone loss in patients on hormone-based ...

Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos (denosumab-nxxp) injection 60 mg/ml and Bilprevda (denosumab-nxxp) injection 120 mg/1.7 ...

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the United States for all approved indications. Conexxence is approved for use ...

Bildyos and Bilprevda are FDA-approved biosimilars to Prolia and Xgeva, expanding access to bone care treatments in the U.S. Bildyos treats osteoporosis and bone loss in cancer therapies, while ...